-
1 Comment
Porton Pharma Solutions Ltd is currently in a long term uptrend where the price is trading 55.2% above its 200 day moving average.
From a valuation standpoint, the stock is 43.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Porton Pharma Solutions Ltd's total revenue rose by 24.3% to $584M since the same quarter in the previous year.
Its net income has increased by 71.4% to $85M since the same quarter in the previous year.
Finally, its free cash flow fell by 64.5% to $37M since the same quarter in the previous year.
Based on the above factors, Porton Pharma Solutions Ltd gets an overall score of 3/5.
Exchange | SHE |
---|---|
CurrencyCode | CNY |
Industry | Drug Manufacturers - Specialty & Generic |
ISIN | CNE100001S57 |
Sector | Healthcare |
Beta | 0.4 |
---|---|
Market Cap | 8B |
PE Ratio | None |
Target Price | 21.5 |
Dividend Yield | 3.5% |
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Porton Pharma Solutions and Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. The company operates in China and internationally. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. Porton Pharma Solutions Ltd. was incorporated in 2005 and is headquartered in Chongqing, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300363.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025